| Code | CSB-RA004936MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Dalnicastobart, targeting CD40, a crucial costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, B cells, and various non-immune cells, playing a central role in adaptive immunity by regulating B cell activation, immunoglobulin class switching, and germinal center formation. The CD40-CD40L interaction is critical for immune homeostasis, and dysregulation of this pathway has been implicated in autoimmune diseases, inflammatory conditions, and hematological malignancies including multiple myeloma and B cell lymphomas.
Dalnicastobart is an investigational agonistic anti-CD40 antibody originally developed to enhance anti-tumor immune responses by activating dendritic cells and promoting T cell priming. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune activation, exploring novel immunotherapeutic strategies in oncology, and studying the molecular mechanisms underlying CD40 signaling in both normal and pathological contexts. The antibody supports diverse experimental approaches in immunology and cancer biology research.
There are currently no reviews for this product.